Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Supports conservative management of neurocardiogenic syncope given absent proven therapies; leaves open identification of effective treatments through future trials.
Neurocardiogenic syncope is one of the most common types of syncope, characterized by arterial vasodilatation with or without bradycardia. The regulation of blood pressure and heart rate is the result of a complex reaction between the central and peripheral nervous system with the circulatory system. Multiple therapies, pharmaceutical and interventional, have been applied without any proven effect. The initial positive reports on pacing were not demonstrated in enough number of controlled studies. Neurocardiogenic syncope continues to remain a clinical problem in terms of understanding its underlying mechanisms and therapy needs to be enlightened by future studies. This article provides a background of diagnosis and therapy of neurocardiogenic syncope and reviews some related patents.
No takes yet. Share an insight, caveat, or question.
Κωστοπούλου et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: